Bcma Car-T is named as an intervention in 4 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (3). The most-studied condition is Multiple Myeloma, Newly Diagnosed.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study
NCT07435779 · ClinicalTrials.gov ↗ · UC
|
Phase EARLY_PHASE1 | Recruiting | Hebei Senlang Biotechnology Inc., Ltd. | China |
|
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
NCT07106684 · ClinicalTrials.gov ↗ · Multiple Myeloma, Plasma Cell Leukemia
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
NCT07106710 · ClinicalTrials.gov ↗ · Multiple Myeloma, Newly Diagnosed
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
NCT07106736 · ClinicalTrials.gov ↗ · Multiple Myeloma, Newly Diagnosed
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Hebei Senlang Biotechnology Inc., Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 4 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Bcma Car-T as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 4 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Institute of Hematology & Blood Diseases Hospital, China (3) and Hebei Senlang Biotechnology Inc., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Bcma Car-T works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Bcma Car-T works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Bcma Car-T (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.